Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). SSY Group's share price for the quarter that ended in Dec. 2023 was HK$4.94. SSY Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 2,969 Mil. Therefore, SSY Group's market cap for the quarter that ended in Dec. 2023 was HK$14,667 Mil.
SSY Group's quarterly market cap
increased
from Dec. 2022 (HK$12,817 Mil) to Jun. 2023 (HK$14,850 Mil) but then
declined
from Jun. 2023 (HK$14,850 Mil) to Dec. 2023 (HK$14,667 Mil).
SSY Group's annual market cap
increased
from Dec. 2021 (HK$12,047 Mil) to Dec. 2022 (HK$12,817 Mil) and
increased
from Dec. 2022 (HK$12,817 Mil) to Dec. 2023 (HK$14,667 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SSY Group's Enterprise Value for Today is HK$16,248 Mil.
SSY Group Market Cap Historical Data
The historical data trend for SSY Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Market Cap distribution charts can be found below:
* The bar in red indicates where SSY Group's Market Cap falls into.
SSY Group Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SSY Group's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (HKSE:02005) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SSY Group Market Cap Related Terms
Thank you for viewing the detailed overview of SSY Group's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02005 has been successfully added to your 